PERCEPTIVE ADVISORS LLC
NEW YORK, NY · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$5.34B2026 Q3+ $399.9M options (notional, not included)
Positions108
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.49.7%
What Changed This Quarter?
Top Holdings
PRAX
Praxis Precision Medicines
10.3%
AMLX
Amylyx Pharmaceuticals
5.4%
SYRE
Spyre Therapeutics
5.1%
MRNAPUT
Moderna
4.7%
CELC
Celcuity
4.4%
RYTM
Rhythm Pharmaceuticals
4.2%
ROIV
Roivant Sciences
4.1%
RLAY
Relay Therapeutics
4.0%
New / Increased
26 new · 15 increased
FRNMNEW
Freenome
3.5%
WATNEW
Waters
1.0%
IRDNEW
Opus Genetics
0.8%
SLSCALLNEW
Sellas Life Sciences
0.6%
LKFTNEW
Lakefront Biotherapeutics
0.6%
MRNAPUT
Moderna
4.7%
+40.0%
AMLX
Amylyx Pharmaceuticals
5.4%
+26.9%
NRIX
Nurix Therapeutics
2.2%
+24.3%
Reduced / Exited
42 reduced · 27 sold out
SYRE
Spyre Therapeutics
5.1%
-24.0%
ROIV
Roivant Sciences
4.1%
-19.5%
BIIB
Biogen
0.1%
-89.9%
ASND
Ascendis Pharma A/S
3.9%
-16.5%
UNH
UnitedHealth
0.1%
-91.4%
NUVLEUREXIT
Nuvalent
2.9%
Apogee Therap…EXIT
Apogee Therapeutics
2.6%
IONSEXIT
Ionis Pharmaceuticals
0.7%
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.